Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03848065
Other study ID # V114-028
Secondary ID 194669
Status Completed
Phase Phase 1
First received
Last updated
Start date April 2, 2019
Est. completion date June 24, 2020

Study information

Verified date May 2024
Source Merck Sharp & Dohme LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V114 administered subcutaneously or intramuscularly in healthy Japanese infants (3 months of age).


Recruitment information / eligibility

Status Completed
Enrollment 133
Est. completion date June 24, 2020
Est. primary completion date June 24, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Months to 3 Months
Eligibility Inclusion Criteria: - Healthy (based on a review of medical history and physical examination) based on the clinical judgment of the investigator. - Male or female 3 months of age inclusive (3 months of age to1 day prior to 4 months of age), at the time of obtaining the informed consent. - Has a legally acceptable representative who understands the study procedures, alternate treatments available, and risks involved with the study and voluntarily agrees to participate by giving written informed consent. Exclusion Criteria: - Has a history of invasive pneumococcal disease (positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture positive pneumococcal disease. - Has a known hypersensitivity to vaccines, any component of the pneumococcal conjugate vaccine or any diphtheria toxoid-containing vaccine - Has any contraindication to the PCV13 and/or diphtheria, tetanus, acellular pertussis, inactivated polio vaccine (DTaP-IPV) being administered in the study (Refer to approved labeling for contraindication details on PCV13 and DTaPIPV vaccine). - Has a recent febrile illness (axillary temperature =37.5°C) occurring within 72 hours prior to receipt of study vaccine. - Has a known or suspected impairment of immunological function. - Has a history of congenital or acquired immunodeficiency. - Has or his/her mother has a documented hepatitis B surface antigen - positive test. - Has a known functional or anatomic asplenia. - Has failure to thrive based on the clinical judgement of the investigator. - Has thrombocytopenia or a known coagulation disorder contraindicating intramuscular vaccination. - Has a history of autoimmune disease (including but not limited to systemic lupus erythematosus, antiphospholipid syndrome, Bechet's disease, autoimmune thyroid disease, polymyositis and dermatomyositis, scleroderma, type 1 diabetes mellitus, or other autoimmune disorders). - Has a known neurologic or cognitive behavioral disorder, including encephalitis/myelitis, acute disseminating encephalomyelitis, pervasive development disorder, and related disorders. - Has received a dose of any pneumococcal and/or DTaP-IPV vaccine (or vaccine containing any DTaP-IPV component) prior to study entry. - Meets one or more of the following systemic corticosteroid exclusion criteria: has received systemic corticosteroids (equivalent of = 2 mg/kg total daily dose of prednisone or = 20 mg/d for persons weighing > 10 kg) for = 14 consecutive days and has not completed this course of treatment at least 30 days prior to trial randomization, has received systemic corticosteroids within 14 days prior to the first dose of study vaccine at randomization, and is expected to require systemic corticosteroids (equivalent of = 2 mg/kg total daily dose of prednisone or = 20 mg/d for persons weighing > 10 kg) for = 14 consecutive days within 14 days prior to or 30 days after each vaccination during conduct of the study.(Topical, ophthalmic and inhaled steroids are permitted.) - Has received other licensed non-live vaccines within the 14 days before receipt of first dose of study vaccine. - Has received a licensed live virus vaccine within the 28 days before receipt of first dose of study vaccine. - Has received a blood transfusion or blood products, including immunoglobulins before receipt of first dose of study vaccine. - Has participated in another clinical study of an investigational product before the beginning or anytime during the duration of the current clinical study. Participants enrolled in observational studies may be included; these will be reviewed on a case by case basis for approval by the Sponsor. - Has any other reason that, in the opinion of the investigator, may interfere with the evaluation required by the study. (Refer to the Vaccination Guideline in Japan). Reasons may include, but are not limited to, being unable to keep appointments or planning to relocate during the study. - Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
V114
15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
Pneumococcal 13-valent Conjugate Vaccine (PCV13)
13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)
Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).

Locations

Country Name City State
Japan Hidaka Children's Clinic ( Site 2803) Dazaifu Fukuoka
Japan Kobayashi Pediatric Clinic ( Site 2816) Fujieda Shizuoka
Japan Fukui Aiiku Hospital ( Site 2809) Fukui
Japan Fukui-ken Saiseikai Hospital ( Site 2813) Fukui
Japan Isesaki Municipal Hospital ( Site 2806) Isesaki Gunma
Japan Sotobo Children's Clinic ( Site 2807) Isumi Chiba
Japan Kawasaki Municipal Hospital ( Site 2802) Kawasaki Kanagawa
Japan Meitetsu Hospital ( Site 2805) Nagoya Aichi
Japan Kubota Children's Clinic ( Site 2815) Osaka
Japan Japanese Red Cross Shizuoka Hospital ( Site 2817) Shizuoka
Japan Suita Municipal Hospital ( Site 2801) Suita Osaka
Japan Nishida Kodomo Clinic ( Site 2811) Tama Tokyo
Japan Hosaka Children's Clinic ( Site 2814) Tokyo
Japan Yokosuka Kyosai Hospital ( Site 2804) Yokosuka Kanagawa

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Ishihara Y, Kuroki H, Hidaka H, Iwai K, Wan K, Shirakawa M, Sawata M. Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028). Hum Vaccin Immunother. 2023 Dec 31;19(1):2180973. doi: 1 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With a Solicited Injection-site Adverse Event (AE) An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs were injection site erythema (redness), injection site induration (hard lump), injection site pain and injection site swelling. Day 1 to Day 14 post each vaccination
Primary Percentage of Participants With a Solicited Systemic Adverse Event An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs were decreased appetite (appetite loss), somnolence (drowsiness), irritability and urticaria (hives/welts). Day 1 to Day 14 post each vaccination
Primary Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE) An SAE is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Up to 4 weeks post vaccination 4 (~14.5 months)
Secondary Percentage of Participants Meeting the Serotype-specific Immunoglobulin G (IgG) Threshold of =0.35 µg/mL Serotype-specific pneumococcal IgG antibody was measured using pneumococcal electrochemiluminescence (PnECL). The percentage of participants with serotype-specific IgG =0.35 µg/mL was summarized for each serotype. One month post vaccination 3 (~3 months after Vaccination 1)
Secondary Serotype-specific IgG Geometric Mean Concentrations (GMCs) The anti-pneumococcal polysaccharide (PnPs) serotype-specific IgG Geometric Mean Concentrations (GMCs) were determined using an electrochemiluminescence assay. 1 month post vaccination 3 (~3 months after Vaccination 1)
Secondary Percentage of Participants Meeting Threshold Values for Protective Responses to DTaP-IPV (Diphtheria Toxin, Tetanus Toxin, Pertussis Toxin, Pertussis Filamentous Hemagglutinin (FHA) and Polio Virus Type 1/2/3) DTaP-IPV antibody titers were measured by neutralization assay (diphtheria toxin and poliovirus 1/2/3), particle agglutination assay (tetanus toxin) and enzyme-linked immunosorbent assay (ELISA) methodology (pertussis PT and pertussis FHA) 1 month post vaccination 3. Threshold values were: Diphtheria toxin level =0.1 IU/mL, Pertussis PT level =10 EU/mL, Pertussis FHA level =10 EU/mL, Tetanus toxin level =0.01 IU/mL, Neutralizing antibody (NA) titers of Polio virus types 1/2/3 =1:8. 1 month post vaccination 3 (~3 months after Vaccination 1)
See also
  Status Clinical Trial Phase
Completed NCT02201030 - Immunogenicity and Safety Study of NBP606 in Healthy Infants Phase 3
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Completed NCT04031846 - Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) Phase 3
Recruiting NCT05920499 - The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage N/A
Completed NCT01215175 - Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001) Phase 1
Completed NCT02892812 - A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults Phase 1
Completed NCT02116998 - Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae Phase 2
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01193582 - A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria Phase 4
Completed NCT00744263 - Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults Phase 4
Completed NCT00492557 - Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults Phase 3
Completed NCT00195611 - Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media Phase 4
Completed NCT00137605 - Early Versus Delayed Pneumococcal Vaccination in HIV Phase 1/Phase 2
Completed NCT00205803 - Study Evaluating Pneumococcal Vaccine in Healthy Infants Phase 1/Phase 2
Completed NCT02531373 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005) Phase 1/Phase 2
Completed NCT03615482 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) Phase 3
Completed NCT03565900 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) Phase 3
Completed NCT04989465 - A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine Phase 4
Completed NCT02547649 - Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) Phase 2
Completed NCT02573181 - Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) Phase 2